ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

Lancet

Volumn 352, Issue 9140, 1998, Pages 1571-1576

  Parmar, M K B ^a,b   Torri, V ^c   Bonaventura, A ^c   Bonazzi, C ^c   Colombo, N ^c   Delaloye, J F ^c   Marsoni, S ^c   Mangioni, C ^c   Sandercock, J ^c   Sessa, C ^c   Williams, C ^c   Tinazzi, A ^c   Flann, M ^c   Geiser, K ^c   Scorpiglione, N ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 0032517581     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04119-1     Document Type: Article

References (16)

1. 1 Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA-A Cancer J Clin 1994; 44: 7-26.
2. 2 Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer 1993; 71: 517.
3. 3 Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA-A Cancer J Clin 1995; 45: 88-101.
4. 4 Hand R, Fregmen A, Chmeil JS, et al. Staging procedures, clinical management and survival outcome for ovarian carcinoma. JAMA 1993; 269: 1119-22.
5. 5 Pettersson F. Annual report on the results of treatment in gynaecological cancer, volume 22. Stockholm: Radiumhemmet, 1995.
6. 6 Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991; 303: 884-93.
7. 7 Ovarian Cancer Meta-Analyses Project. CP vs CAP chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-74.
8. 8 A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
9. 9 Ghersi D, Parmar MKB, Stewart LA, Marsoni S, Williams C. Early ovarian cancer and the ICON trials. Eur J Cancer 1992; 28A: 1297.
10. 10 Calvert AH, Urie J. The costs of carboplatin treatment. Semin Oncol 1991; 18: 28-31.
11. 11 Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaulation of simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
12. 12 Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester: John Wiley, 1995.
13. 13 Skarlos DV, Arvantinos G, Kosmidis P, et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic cooperative oncology group study. Eur J Cancer 1996; 12A: 421-28.
14. 14 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
15. 15 Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup trial. Proc Am Soc Clin Oncol 1998; 17: abstr 1394, 361a.
16. 16 Muggia FM, Braly PS, Brady MF, et al, for the Gynaecology Oncology Group (Buffalo, NY, USA). Phase III trial of cisplatin (P) or paclitaxel (T) versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynacology Oncology Group (GOG) Study 132. Proc Am Soc Clin Oncol 1997; 16: abstr number 1257, 352a.